Zenphia is a Translational Infrastructure Platform that integrates IP strategy, regulatory pathway design, clinical architecture, leadership deployment, and venture creation under one roof — upstream, before the structural mistakes are made that doom most life sciences companies before they begin.
of life sciences research never reaches patients — not because the science fails, but because the infrastructure around it does. IP strategy is misaligned with regulatory timelines. Clinical trials launch before safety systems exist. Leadership is deployed at the wrong phase. Capital is raised before the foundation exists to use it.
Most life sciences companies hire five to seven disconnected specialists who make critical decisions in silos. The result is predictable: FDA delays, wasted capital, and breakthrough therapies that never reach the people who need them.
Zenphia was built to fix that.
"Founders don't fail for lack of ambition or expertise. They fail for lack of integrated execution infrastructure deployed at the right time."
— Peter Yassopoulos, Founder & CEO
Most competitors offer one or two. Zenphia delivers all six — integrated, sequenced, and deployed upstream before structural mistakes become irreversible.
After 44 years placing C-suite leaders in life sciences, Peter Yassopoulos has made a deliberate transition — from executive recruiter to Broad Talent Advisory Consultant. The difference is the difference between filling a role and shaping how an organization thinks about human capital, leadership architecture, and the relationship between its people strategy and its mission.
"When everyone sources from the same active candidate pool, filling hard roles means reaching the people who aren't looking." — LinkedIn, 2026
LinkedIn is right about the problem. A technology platform is not the answer.
The candidates who actually solve your most critical leadership problems are not in any database. They are not responding to job postings. They are not on any recruiter's radar. They will only take one call — from someone they have known and trusted for decades.
That is not a technology problem. It is a relationship problem. And it is precisely what 44 years of pattern recognition in life sciences was built to solve.
A structured assessment of a company's entire senior leadership team — identifying gaps, redundancies, succession risks, and organizational design weaknesses. Deliverable is a written report with specific, prioritized recommendations. Designed for boards and CEOs preparing for a clinical inflection point, a commercial transition, or a new financing round.
Ongoing quarterly advisory to a board or CEO on talent strategy, compensation benchmarking, organizational design, and succession planning. Retainer-based. Peter serves as the board's pattern recognition resource on every human capital question that arises — bringing 44 years of observing leadership success and failure in advanced therapeutics directly into the governance conversation.
Advisory for companies navigating a CEO succession, a merger, a post-acquisition integration, or any significant leadership transition — focused on the human dimension of the change. How do you retain the people who matter most during a transition? How do you manage the cultural disruption that leadership change always creates? These are the questions most boards discover too late.
You have assembled your finalist candidates through your own process. Zenphia conducts structured evaluations of each — reviewing materials and conducting direct conversations. We deliver a written Talent Advisory Report within 14 business days: individual candidate analysis, comparative assessment, and a clear hiring recommendation grounded in 44 years of pattern recognition.
The same structured evaluation process extended to a larger finalist pool. Ideal for searches where the board has strong internal candidates alongside external finalists and needs an independent, experienced voice to cut through the internal politics and deliver an honest recommendation.
End-to-end retained executive search for CEOs, CMOs, CSOs, CROs, and CDOs in gene therapy, oncology, and advanced biologics. Conducted selectively — Peter accepts only engagements where his specific pattern recognition in advanced therapeutics is the differentiating factor. Grounded in 44 years of direct relationships with proven operators in the field.
The wrong C-suite hire in gene therapy or oncology is not an HR problem. It is an existential one. Every service in this practice — from the Board Advisory retainer to the full retained search — exists to ensure that the most important decisions a board makes about its people are made with the benefit of the deepest available pattern recognition in advanced therapeutics.
Following strategic review, Zenphia has sharpened its positioning around five core priorities that maximize credibility, deal flow, and long-term platform value.
In life sciences, sequence matters. IP strategy must inform the regulatory pathway. The regulatory pathway must inform clinical design. Clinical design must inform product specifications. Commercialization timelines must inform leadership deployment.
When these decisions are made in silos by disconnected specialists, structural failure is inevitable. When they are integrated by a single partner who understands the complete path from lab to market, breakthrough science actually reaches the world.
"Founders don't fail for lack of ambition or expertise. They fail for lack of integrated execution infrastructure deployed at the right time."— Peter Yassopoulos, Founder & CEO
Apex Protocol is Zenphia's proprietary leadership intelligence infrastructure — being built to make 44 years of pattern recognition measurable, verifiable, and transferable beyond any single individual. It is not a portfolio company. It is the intelligence layer that makes Zenphia itself more defensible, more scalable, and more valuable to every client and investor it serves.
"Leadership performance is not a trait. It is a measurable system effect over time. Execution velocity, cultural stability under stress, decision quality under uncertainty — these signals exist in every organization. Until now, no platform has been designed to capture, validate, and translate them into decision-grade intelligence. Apex Protocol is that platform."
— Peter Yassopoulos, Founder & CEO, ZenphiaApex captures, validates, and synthesizes real-world leadership signals into decision-grade intelligence — replacing résumé-based evaluation with longitudinal, outcome-verified insight. It surfaces early warning signals of execution and cultural risk before failure occurs, giving boards, investors, and institutions the clarity they need before deploying capital or trust.
Apex is not executive search. Not HR tech. Not AI résumé matching. Not a coaching platform. Not a psychometric test. Those categories optimize for placement — not outcomes. Apex operates in a category that does not yet exist: Leadership Risk Intelligence. It is a system of record for leadership execution, built on the premise that pattern recognition deployed upstream is the rarest and most valuable thing in any high-stakes environment.
Apex is not positioned inside Zenphia because it lacks ambition. It is positioned here because Zenphia already operates at the human-system layer Apex is designed to measure. Every advisory engagement Zenphia conducts is a signal environment. Every leadership deployment creates observable data. Every governance structure built generates the longitudinal evidence Apex is designed to capture.
This is not a convenient relationship. It is a strategic one. Apex compounds in value precisely because it is embedded in Zenphia's highest-stakes institutional work — not because it is sold broadly to a mass market.
The long-term architecture is deliberate: Zenphia incubates Apex. Apex makes Zenphia's pattern recognition institutional. When the market is ready to receive a standalone leadership intelligence platform, Apex spins out — with Zenphia as its founding shareholder and its most credible institutional proof point.
Zenphia co-builds companies and platforms with equity participation from formation. Every portfolio entity launches with complete execution infrastructure already in place — from IP strategy through leadership deployment.
VectorGen is pioneering A-Frame — a patented next-generation lentivector platform with CRISPR-based site-specific integration, conditional self-inactivation, and large multi-gene payload capacity. Initial focus: HIV functional cure. Platform extensible to oncology, neurology, and regenerative medicine.
The Koinon Center is a 501(c)(3) nonprofit dedicated to helping American communities transition from industrial legacies to diverse, knowledge-based economies centered on innovation, sustainability, and the arts. Through IP education, entrepreneurial capacity building, university partnerships, and community-led workforce development, The Koinon Center gives citizens the tools to build fulfilling lives and thriving cities. Named for the ancient Greek word for commonwealth — the root of the word "community" itself.
Planet.Bio is a curated life sciences executive career intelligence platform built on 44 years of pattern recognition in C-suite executive search. The platform publishes original market intelligence — including quarterly Executive Transition Intelligence Reports, the annual Planet.Bio Power List, and the Pattern Recognition podcast — positioning it as the most authoritative independent voice in advanced therapeutics leadership intelligence. Active SEO growth phase with the Adzuna API powering live C-suite job listings.
Longitude is a standalone precision executive coaching practice for life sciences founders, CEOs, and senior leaders navigating critical inflection points. Operating independently at longitudeadvisors.com — selectively by design, built entirely on pattern recognition.
Profile Architect transforms underselling LinkedIn profiles into precision career instruments — built on 44 years of understanding how sophisticated readers in life sciences actually evaluate professional credibility. Not cosmetic changes. Strategic rewrites that change what happens when the right person finds you.
A structured revenue architecture that generates income at every stage of engagement — from initial assessment through full venture co-creation.
Building a life sciences venture is not just a scientific challenge. It is a strategic, financial, and organizational one. Zenphia works with a small number of early stage founders to help them get investor ready, position their narrative, and connect with the right capital at the right moment.
Most early stage life sciences founders have extraordinary science and a deeply inadequate funding strategy. They approach investors before they are investor ready. They pitch the science when investors are evaluating the team, the market, and the exit. And they spend years talking to the wrong people.
The result is not failure of science. It is failure of positioning, narrative, and access. Those are solvable problems — if you have the right infrastructure around you.
We work with you to ensure your science, your team story, your market positioning, and your financial ask are structured in the language that serious investors actually use to evaluate opportunities in advanced therapeutics.
Partner: Higgs Insights — a specialist advisory firm connecting early stage life sciences ventures with strategic VC introductions.
After 44 years placing senior leaders in life sciences we understand how the most sophisticated readers in this industry evaluate a company, a team, and a thesis. We help founders build the story that gets them in the room — and keeps them there.
This includes executive summary development, pitch deck narrative review, and LinkedIn positioning for founding teams.
44 years of direct relationships with the operators, investors, and board members who have actually built and funded companies in gene therapy, oncology, and advanced biologics. We make introductions when there is a genuine fit — not before.
Access is earned through the quality of the venture and the readiness of the team. We do not introduce founders who are not ready.
Zenphia Venture Services works with a small number of founders at any one time. We are not a pitch contest or a demo day. We are a focused, long-term strategic partnership for founders who are serious about building something that reaches patients.
The right fit is a founder in gene therapy, oncology, advanced biologics, or adjacent therapeutic areas who has compelling science, a defined clinical thesis, and the intellectual honesty to recognize that getting funded requires more than a good slide deck.
Every engagement begins with a conversation. No agenda. No obligation. Just an honest assessment of where you are and what you need.
Begin the Conversation →Whether you are a life sciences founder, a research institution, an investor, or a law firm partner — we would love to explore whether there is a fit.
Founder & CEO, Zenphia
"We build that infrastructure. We deploy it upstream. And we do it in service of something larger than any single company — ensuring that breakthrough science reaches the people and communities who need it most."
Longitude is a precision executive coaching practice built entirely for life sciences leaders — founders, CEOs, and senior executives navigating the moments that define what comes next. It is not motivational coaching. It is not a framework with acronyms. It is something rarer — a guided encounter with your own pattern of leadership, delivered by someone who has watched that pattern play out thousands of times before.
Every leader has a pattern — a consistent architecture of strengths, blind spots, and behavioral tendencies that repeats across contexts. Longitude begins by making that pattern visible. You cannot navigate deliberately from a position you cannot see.
Longitude is not a general coaching practice that happens to have life sciences clients. It is built entirely for the specific pressures, rhythms, and human dynamics of biotech, pharma, gene therapy, and advanced therapeutics — where leadership failure carries consequences measured in years, capital, and lives.
The foundation of Longitude is not a coaching certification. It is 44 years of watching thousands of leadership careers unfold in real time — what worked, what failed, and why the difference was almost never what the leader expected it to be.
"My last coaching client did not simply become a better executive. She became the founder of a gene therapy venture company working to develop a functional cure for HIV. That outcome is what coaching at this depth — and this specificity — can produce."
For leaders with a specific and bounded question. The natural entry point for those considering a longer engagement — conducted with the same depth and candor as the full practice.
For leaders at a specific crossroads — a financing event, a leadership transition, a pivotal strategic decision. Fixes your position at the moment that matters most.
The full engagement — for leaders who understand that the most important coaching is longitudinal, not situational. Includes quarterly written synthesis and annual outcome review.
Every engagement begins with a complimentary Orientation Conversation — no agenda, no obligation. If there is a fit, we will know it in the first conversation.
The same conviction that drives Zenphia's institutional platform — that the right infrastructure deployed at the right moment determines whether a promising idea reaches the world — applies equally at the community level. Zenphia Community is how we deliver that conviction to entrepreneurs, local business owners, and aspiring innovators who have never had access to it.
In 1727, a 21-year-old Benjamin Franklin gathered twelve tradesmen and artisans in Philadelphia for a weekly meeting he called the Junto. They came together not to network or to pitch — but to ask genuine questions, share practical knowledge, and hold each other accountable to growth. It became one of the most productive intellectual communities in American history.
Entrepreneurship is not a personality trait. It is a learnable skill acquired through doing — through structured participation in community with others who are building alongside you. The Zenphia Commons is where this capacity develops.
Every entrepreneur has ideas worth protecting. Most have no access to the IP strategy that turns those ideas into competitive assets. Zenphia makes IP expertise accessible at the community level — not just for life sciences companies but for local innovators, craftspeople, and small manufacturers.
The most resilient entrepreneurial communities build their own infrastructure rather than waiting for institutional support. Zenphia Community is built on the conviction that genuine engagement — peer to peer, neighbor to neighbor — is more durable than any government program.
Building something meaningful is simultaneously an outer and an inner act. The development of entrepreneurial, creative, and manufacturing capacities is a form of personal and collective growth — and the Zenphia Community program honors that explicitly.
Globalization and outsourcing stripped American communities of the practical knowledge of how to make things. Zenphia Community works to restore that knowledge — helping entrepreneurs understand prototyping, production, and scaling as learnable skills that can be rebuilt locally.
The Commons runs as a structured twelve-week cohort — groups of twelve to fifteen community participants meeting weekly. Each session focuses on one of the five capacities in sequence, building from entrepreneurial mindset through IP strategy, community engagement, personal development, and manufacturing fundamentals.
Part of Zenphia Community's mission is finding and mapping environments where regulatory barriers to entrepreneurial entry are low — and actively guiding participants toward those pathways as part of the strategic package. The system is not neutral. Knowing how to navigate it is a competitive advantage that most community entrepreneurs never receive.
Zenphia Community is mission-driven but financially sustainable. Revenue is generated through three complementary streams that reinforce rather than compromise the program's integrity.
A modest monthly membership of $20 to $50 covers operational costs and signals commitment. People value what they invest in. Franklin's original Junto members paid dues.
Local banks, credit unions, community foundations, and economic development organizations actively fund entrepreneurship programs. Zenphia Community is exactly what these funders are looking for.
Business owners who want individual attention beyond the group sessions engage in monthly one-on-one strategic advisory at $500 to $1,000 per month — the Zenphia Strategic Advisory model applied at the community level.
"The same infrastructure that gets breakthrough science from the lab to the patient is what gets a neighborhood entrepreneur's idea from a napkin to a thriving business. The principles are identical. The stakes are equally real."— Peter Yassopoulos, Founder & CEO, Zenphia